vs
ANI PHARMACEUTICALS INC（ANIP）与Essex Property Trust（ESS）财务数据对比。点击上方公司名可切换其他公司
Essex Property Trust的季度营收约是ANI PHARMACEUTICALS INC的1.9倍（$479.6M vs $247.1M），Essex Property Trust净利率更高（17.9% vs 11.1%，领先6.8%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 5.5%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 6.0%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
ANIP vs ESS — 直观对比
营收规模更大
ESS
是对方的1.9倍
$247.1M
营收增速更快
ANIP
高出24.1%
5.5%
净利率更高
ESS
高出6.8%
11.1%
两年增速更快
ANIP
近两年复合增速
6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $479.6M |
| 净利润 | $27.5M | $85.7M |
| 毛利率 | — | 70.0% |
| 营业利润率 | 14.1% | 31.7% |
| 净利率 | 11.1% | 17.9% |
| 营收同比 | 29.6% | 5.5% |
| 净利润同比 | 367.5% | -71.6% |
| 每股收益（稀释后） | $1.14 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPESS
| Q4 25 | $247.1M | $479.6M | ||
| Q3 25 | $227.8M | $473.3M | ||
| Q2 25 | $211.4M | $469.8M | ||
| Q1 25 | $197.1M | $464.6M | ||
| Q4 24 | $190.6M | $454.5M | ||
| Q3 24 | $148.3M | $450.7M | ||
| Q2 24 | $138.0M | $442.4M | ||
| Q1 24 | $137.4M | $426.9M |
净利润ANIPESS
| Q4 25 | $27.5M | $85.7M | ||
| Q3 25 | $26.6M | $172.7M | ||
| Q2 25 | $8.5M | $231.5M | ||
| Q1 25 | $15.7M | $212.8M | ||
| Q4 24 | $-10.3M | $301.7M | ||
| Q3 24 | $-24.2M | $125.5M | ||
| Q2 24 | $-2.3M | $99.0M | ||
| Q1 24 | $18.2M | $285.1M |
毛利率ANIPESS
| Q4 25 | — | 70.0% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 70.7% | ||
| Q1 25 | — | 69.6% | ||
| Q4 24 | — | 70.0% | ||
| Q3 24 | — | 69.5% | ||
| Q2 24 | — | 70.8% | ||
| Q1 24 | — | 69.7% |
营业利润率ANIPESS
| Q4 25 | 14.1% | 31.7% | ||
| Q3 25 | 15.9% | 44.5% | ||
| Q2 25 | 6.6% | 59.5% | ||
| Q1 25 | 13.3% | 55.3% | ||
| Q4 24 | -2.3% | 67.0% | ||
| Q3 24 | -13.8% | 28.6% | ||
| Q2 24 | 3.7% | 31.1% | ||
| Q1 24 | 14.8% | 31.0% |
净利率ANIPESS
| Q4 25 | 11.1% | 17.9% | ||
| Q3 25 | 11.7% | 36.5% | ||
| Q2 25 | 4.0% | 49.3% | ||
| Q1 25 | 8.0% | 45.8% | ||
| Q4 24 | -5.4% | 66.4% | ||
| Q3 24 | -16.3% | 27.8% | ||
| Q2 24 | -1.7% | 22.4% | ||
| Q1 24 | 13.2% | 66.8% |
每股收益（稀释后）ANIPESS
| Q4 25 | $1.14 | $1.24 | ||
| Q3 25 | $1.13 | $2.56 | ||
| Q2 25 | $0.36 | $3.44 | ||
| Q1 25 | $0.69 | $3.16 | ||
| Q4 24 | $-0.45 | $4.00 | ||
| Q3 24 | $-1.27 | $1.84 | ||
| Q2 24 | $-0.14 | $1.45 | ||
| Q1 24 | $0.82 | $4.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $76.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $5.5B |
| 总资产 | $1.4B | $13.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPESS
| Q4 25 | $285.6M | $76.2M | ||
| Q3 25 | $262.6M | $66.0M | ||
| Q2 25 | $217.8M | $58.7M | ||
| Q1 25 | $149.8M | $98.7M | ||
| Q4 24 | $144.9M | $66.8M | ||
| Q3 24 | $145.0M | $71.3M | ||
| Q2 24 | $240.1M | $55.2M | ||
| Q1 24 | $228.6M | $499.0M |
总债务ANIPESS
| Q4 25 | — | — | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.2B | ||
| Q1 24 | — | $6.6B |
股东权益ANIPESS
| Q4 25 | $540.7M | $5.5B | ||
| Q3 25 | $505.8M | $5.6B | ||
| Q2 25 | $436.8M | $5.6B | ||
| Q1 25 | $418.6M | $5.6B | ||
| Q4 24 | $403.7M | $5.5B | ||
| Q3 24 | $405.9M | $5.4B | ||
| Q2 24 | $455.8M | $5.5B | ||
| Q1 24 | $452.0M | $5.5B |
总资产ANIPESS
| Q4 25 | $1.4B | $13.2B | ||
| Q3 25 | $1.4B | $13.2B | ||
| Q2 25 | $1.3B | $13.2B | ||
| Q1 25 | $1.3B | $13.2B | ||
| Q4 24 | $1.3B | $12.9B | ||
| Q3 24 | $1.3B | $12.6B | ||
| Q2 24 | $920.8M | $12.5B | ||
| Q1 24 | $914.5M | $12.9B |
负债/权益比ANIPESS
| Q4 25 | — | — | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.22× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | — | 1.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $1.1B |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | 12.53× |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPESS
| Q4 25 | $30.4M | $1.1B | ||
| Q3 25 | $44.1M | $342.6M | ||
| Q2 25 | $75.8M | $216.1M | ||
| Q1 25 | $35.0M | $281.5M | ||
| Q4 24 | $15.9M | $1.1B | ||
| Q3 24 | $12.5M | $316.2M | ||
| Q2 24 | $17.4M | $218.9M | ||
| Q1 24 | $18.3M | $314.9M |
自由现金流ANIPESS
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPESS
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPESS
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
现金转化率ANIPESS
| Q4 25 | 1.10× | 12.53× | ||
| Q3 25 | 1.66× | 1.98× | ||
| Q2 25 | 8.87× | 0.93× | ||
| Q1 25 | 2.23× | 1.32× | ||
| Q4 24 | — | 3.54× | ||
| Q3 24 | — | 2.52× | ||
| Q2 24 | — | 2.21× | ||
| Q1 24 | 1.00× | 1.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ESS
暂无分部数据
